BR112019024249A2 - Métodos e tratamento de trauma - Google Patents

Métodos e tratamento de trauma Download PDF

Info

Publication number
BR112019024249A2
BR112019024249A2 BR112019024249-0A BR112019024249A BR112019024249A2 BR 112019024249 A2 BR112019024249 A2 BR 112019024249A2 BR 112019024249 A BR112019024249 A BR 112019024249A BR 112019024249 A2 BR112019024249 A2 BR 112019024249A2
Authority
BR
Brazil
Prior art keywords
methods
trauma
treatment
hemorrhagic
reversing
Prior art date
Application number
BR112019024249-0A
Other languages
English (en)
Inventor
Dunham Andrew
Yoshida Tatsuro
Original Assignee
New Health Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Health Sciences, Inc. filed Critical New Health Sciences, Inc.
Publication of BR112019024249A2 publication Critical patent/BR112019024249A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a métodos para a reversão de choque hemorrágico ou trauma hemorrágico.
BR112019024249-0A 2017-05-19 2018-05-18 Métodos e tratamento de trauma BR112019024249A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508783P 2017-05-19 2017-05-19
US62/508,783 2017-05-19
PCT/US2018/033404 WO2018213714A1 (en) 2017-05-19 2018-05-18 Methods and treatment of trauma

Publications (1)

Publication Number Publication Date
BR112019024249A2 true BR112019024249A2 (pt) 2020-06-02

Family

ID=62528888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024249-0A BR112019024249A2 (pt) 2017-05-19 2018-05-18 Métodos e tratamento de trauma

Country Status (11)

Country Link
US (7) US11026970B2 (pt)
EP (3) EP4112063A1 (pt)
JP (2) JP2020520937A (pt)
CN (1) CN110636850A (pt)
AU (1) AU2018270096A1 (pt)
BR (1) BR112019024249A2 (pt)
CA (1) CA3063445A1 (pt)
ES (2) ES2935691T3 (pt)
MX (1) MX2019013785A (pt)
PT (2) PT3624812T (pt)
WO (1) WO2018213714A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063445A1 (en) * 2017-05-19 2018-11-22 New Health Sciences, Inc. Methods and treatment of trauma
WO2024064723A1 (en) * 2022-09-20 2024-03-28 Hemanext Inc. Oxygen reduced blood for use in the treatment of traumatic brain injury accompanied by hemorrhagic shock

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447987B1 (en) 1978-09-09 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Prolonged storage of red blood cells
US4769318A (en) 1986-06-03 1988-09-06 Ube Industries, Ltd. Additive solution for blood preservation and activation
US4880786A (en) 1987-01-14 1989-11-14 Ube Industries, Ltd. Additive solution for blood preservation and activation
US5476764A (en) 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US5624794A (en) 1995-06-05 1997-04-29 The Regents Of The University Of California Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US6162396A (en) 1997-04-26 2000-12-19 The Regents Of The University Of California Blood storage device and method for oxygen removal
US5789151A (en) 1997-05-15 1998-08-04 The Regents Of The University Of California Prolonged cold storage of red blood cells by oxygen removal and additive usage
US6413713B1 (en) 1998-10-30 2002-07-02 Hyperbaric Systems Method for preserving blood platelets
SG178780A1 (en) 2007-02-12 2012-03-29 Biotempt Bv Treatment of trauma-hemorrhage with short oligopeptides
DK2440239T3 (en) * 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc HEMOGLOBIN FORMATIONS
US9067004B2 (en) * 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
EP2729000B1 (en) 2011-07-05 2022-12-14 Hemanext Inc. A method for extended storage of red blood cells
CN107530377B (zh) * 2015-03-10 2021-09-03 新健康科学股份有限公司 氧减少一次性套件、装置及其使用方法
CN114748503A (zh) * 2015-05-18 2022-07-15 希玛奈克斯特股份有限公司 储存全血的方法及其组合物
US10335538B2 (en) * 2015-12-08 2019-07-02 Priya Visweswaran Balakrishnan System and treatment method to increase circulation and pluripotency of stem and progenitor cells within a patient
MX2018014530A (es) * 2016-05-27 2019-02-21 New Health Sciences Inc Almacenamiento anaerobico de sangre y metodo de inactivacion de patogenos.
JP7053508B2 (ja) * 2016-06-23 2022-04-12 ヘマネクスト インコーポレイテッド 輸血を必要とする患者集団における有害事象を管理するための方法
CA3063445A1 (en) * 2017-05-19 2018-11-22 New Health Sciences, Inc. Methods and treatment of trauma

Also Published As

Publication number Publication date
EP3708174B1 (en) 2022-10-12
JP2020520937A (ja) 2020-07-16
US20210030790A1 (en) 2021-02-04
MX2019013785A (es) 2020-01-13
EP3624812A1 (en) 2020-03-25
WO2018213714A1 (en) 2018-11-22
AU2018270096A1 (en) 2019-11-28
EP3708174A1 (en) 2020-09-16
ES2935691T3 (es) 2023-03-09
US11026971B2 (en) 2021-06-08
PT3708174T (pt) 2023-01-16
EP4112063A1 (en) 2023-01-04
US11576931B2 (en) 2023-02-14
ES2931228T3 (es) 2022-12-27
US20200237818A1 (en) 2020-07-30
US10898517B2 (en) 2021-01-26
US11026970B2 (en) 2021-06-08
US11033581B2 (en) 2021-06-15
US20200376027A1 (en) 2020-12-03
US20230165896A1 (en) 2023-06-01
JP2023063294A (ja) 2023-05-09
US20200197438A1 (en) 2020-06-25
US20200179446A1 (en) 2020-06-11
US20220118008A9 (en) 2022-04-21
US11052110B2 (en) 2021-07-06
EP3624812B1 (en) 2022-08-24
CN110636850A (zh) 2019-12-31
PT3624812T (pt) 2022-11-30
CA3063445A1 (en) 2018-11-22
US20210290669A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001349A1 (es) Composiciones que comprenden cepas bacterianas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
MD3804737T2 (ro) Compoziții care conțin tulpini bacteriene
PH12016501601A1 (en) Cyclopropylamines as lsd1 inhibitors
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
TW201613860A (en) Cyclopropylamines as LSD1 inhibitors
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112019024249A2 (pt) Métodos e tratamento de trauma
CO2019014647A2 (es) Composiciones inmunogénicas
BR112019004102A2 (pt) imunoterapia para poliomavírus
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
AU2018297614A1 (en) Treatment of avascular or hypovascular micro-tumors

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: HEMANEXT INC. (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]